ClinicalTrials.gg
RecruitingNCT07540910Updated Apr 21, 2026

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of EDP-978 in Healthy Adults

A Phase 1 interventional study of EDP-978 and Placebo in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria, sponsored by Enanta Pharmaceuticals, Inc. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Enanta Pharmaceuticals, Inc · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 64 studies in Chronic Urticaria with a site in United States — 9 open to participants now, 17 under way, 6 of them phase 3. Chronic Urticaria · United States.

Planned enrollment
34th of 58
98 · median 132
Started
2026
with 5 others
Phase 1
5 of 64
1 open now
Primary completion
2026-11
later than 5 of 16 live
Registered
63rd of 64
by date

Among the 64 studies in Chronic Urticaria with a site in United States, this one is the 34th largest by planned enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 5 of the 16 other live ones, and was the 63rd registered.

Chronic Urticaria

199 studies on the registry are indexed under Chronic Urticaria; 51 are open to participants now.

Browse Chronic Urticaria studies →

Open to participants now

9 of the 64 studies in Chronic Urticaria with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Chronic Urticaria with a site in United States, or all of them as a file.
02

Study summary

This study is a randomized, double-blind, sponsor-open, placebo-controlled study. It will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered single and multiple doses of EDP-978 in healthy adult subjects.

03

Conditions studied

  • Chronic Inducible Urticaria
  • Chronic Spontaneous Urticaria

Browse trials for

Keywords

  • First-in-Human
  • Single Ascending Dose
  • Multiple Ascending Dose
  • Healthy Participant
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • An document signed and dated by the subject.
  • Healthy male and female subjects of any ethnic origin between the ages of 18 and 65 years, inclusive.

Exclusion criteria

Exclusion Criteria:

  • evidence or history of illness or disease.
  • Infection with (HIV), virus (HBV), or virus (HCV) at screening and infection with SARS-CoV-2 at the Day -1 visit
  • Pregnant or nursing females.
  • History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.
  • A positive urine drug screen at screening or Day -1.
  • Current tobacco smokers or use of tobacco within 3 months prior to screening.
  • Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).
  • History of regular alcohol consumption.
  • Receipt of any vaccine, an agent or biological product within 28 days or 5 times the t½, whichever one is longer, prior to first dose.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (estimated)

Study arms

  • Experimental
    EDP-978 SAD Cohorts

    EDP-978 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, Dose 6 and Dose 7, orally daily in one single administration

    Drug: EDP-978

  • Experimental
    EDP-978 MAD Cohorts

    EDP-978 Dose 1, Dose 2, Dose 3, Dose 4 and Dose 5 orally, once daily for 14 days

    Drug: EDP-978

  • Placebo comparator
    EDP-978 SAD Placebo Cohorts

    Matching placebo, orally, once daily in one single administration

    Drug: Placebo

  • Placebo comparator
    EDP-978 MAD Placebo Cohorts

    Matching placebo, orally, once daily for 14 days

    Drug: Placebo

Interventions

  • DrugEDP-978

    Oral administration

  • DrugPlacebo

    Placebo to match EDP-978, oral administration

06

What researchers measure

Primary outcomes

  1. Safety measured by adverse events

    Time frame: Up to 8 Days in SAD Cohorts

  2. Safety measured by adverse events

    Time frame: Up to 28 Days in MAD Cohorts

Secondary outcomes

  1. Cmax of EDP-978

    Time frame: Up to 5 Days in SAD Cohorts

  2. AUC of EDP-978

    Time frame: Up to 5 Days in SAD Cohorts

  3. Cmax of EDP-978

    Time frame: Up to 18 Days in MAD Cohorts

  4. AUC of EDP-978

    Time frame: Up to 18 Days in MAD Cohorts

  5. Cmax of EDP-938 (FE)

    Food effects on plasma PK parameters of EDP-978

    Time frame: Up to 12 Days in FE SAD Cohort

  6. AUC of EDP-938 (FE)

    Food effects on plasma PK parameters of EDP-978

    Time frame: Up to 12 Days in FE SAD Cohort

07

Study locations

1 of 1 sites recruiting
  • ICON Early Phase
    San Antonio, Texas 78209, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Nov 2026, 7 months after the start.

Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Apr 21, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07540910
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
Apr 1, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Apr 21, 2026

Study contacts

Enanta Pharmaceuticals, Inc
Contact
emartin@enanta.com
(617) 607-0800
Enanta Pharmaceuticals, Inc
study director · Enanta Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion